Currently available GLP-1 receptor agonists include: Exenatide (Byetta, Bydureon BCise) : Available as twice-daily or once-weekly formulations
A study in July 2024 by researchers at Mass Eye and Ear in Boston found that people taking semaglutide for type 2 diabetes or weight loss had a higher risk of developing nonarteritic anterior ischemic optic neuropathy, an eye condition that can cause blindness, than people taking medications other than GLP-1 drugs for diabetes or obesity
DOI: Published online: December 15, 2014 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
So we need to listen and then do further evaluations, says Gonsahn-Bollie
A: Look for suppliers that provide a Certificate of Analysis (COA) , which details the peptides purity and identity